Bioxyne Limited (AU:BXN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bioxyne Limited announced a significant supply agreement expected to generate approximately $28 million over the next 24 months from pharmaceutical cannabis products, with the initial order valued at $1.6 million. The undisclosed customer, citing confidentiality and security reasons, has agreed to a fixed price for the term and has already paid a $900,000 deposit, reinforcing the company’s positive revenue forecast. Bioxyne delayed announcing this market-sensitive contract until certain conditions were met, ensuring the company could meet the customer’s demand and maintain confidentiality as per the agreement.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.